The Turku-based clinical stage biopharmaceutical company Faron Pharmaceuticals reached a new milestone, as the United States Patent and Trademark Office granted a new US Patent for their novel precision cancer immunotherapy drug candidate, bexmarilimab. The patent is of great importance, as the U.S. pharmaceutical market is the largest in the world.
The received patent prevents similar drugs from entering the market because it protects not only the drug developed by Faron itself but also the way the drug binds to its target, the Clever-1 receptor found on the surface of the tumour.
Bexmarilimab is currently being investigated in the ongoing Phase I/II MATINS trial as a potential monotherapy in patients with solid tumours who have exhausted all treatment options.
“We are extremely pleased to receive this key patent approval which grants us market exclusivity up to 2037. The patent is a welcome addition to our existing global IP portfolio for targeting Clever-1 receptor and further strengthens the long-term potential of this next-generation macrophage reprogramming immunotherapy”, said Dr. Markku Jalkanen, Faron’s CEO.
The same patent has been granted in Japan and applications are under review in other key areas including Europe and China.